Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister; Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister; Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister; This spontaneous case was reported by a nurse and describes the occurrence of RASH ERYTHEMATOUS (Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister), RASH PRURITIC (Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister) and RASH VESICULAR (Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister) in a 72-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032M20A) for COVID-19 vaccination.     Concurrent medical conditions included Glaucoma.    On 04-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, the patient experienced RASH ERYTHEMATOUS (Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister), RASH PRURITIC (Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister) and RASH VESICULAR (Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister). The patient was treated with PREDNISONE for Adverse event, at a dose of low dose prednisone for 10 days and PREDNISONE for Adverse event, at a dose of a tapering dose of prednisone at 60, 40, 20 for 1 week at a time. At the time of the report, RASH ERYTHEMATOUS (Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister), RASH PRURITIC (Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister) and RASH VESICULAR (Immediately after receiving the second dose of the vaccine his rash started again and was angrier than previously. It was red, itching, weeping, fluid filled blister) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.  Currently the rash had improved somewhat and now only down the front of both legs, on his hands down to his last knuckles and somewhat on his forearms. The patient had a visit to his family practice doctor and his dermatologist. They had tried using a topical corticosteroid; additional topical steroids and now the patient was only using topical steroids. He had to reduce the use of steroids because of his glaucoma.   This case was linked to MOD-2021-345685 (Patient Link).